Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same ...
Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...
For the many patients with depression who haven't found relief through medication, transcranial magnetic stimulation (TMS)—a ...
In the early phases of depression and psychosis, patients often show altered inflammatory markers in the blood and structural ...
Get tips to manage health anxiety, loneliness, and other mental health challenges that come with chronic inflammatory demyelinating polyneuropathy.
Neuroinflammation, characterized by the activity of glial cells and the secretion of inflammatory cytokines, is a common pathological feature observed ...